New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 9, 2014
09:22 EDTIDIX, AZN, CGIX, ALNY, NSR, TSN, HSH, ADI, HITT, DG, FDO, MRK, ACHN, ODPOn The Fly: Pre-market Movers
HIGHER: Idenix (IDIX), up more than 230% after Merck (MRK) acquires the company for $24.50 per share in cash of $3.85B. Idenix peer Achillion (ACHN) is up 35% after Merck's purchase... Hittite Microwave (HITT), up 29% after Analog Devices (ADI) agrees to acquire the company for $78 per share in cash... Family Dollar (FDO), up 11.6% following upgrade at Jefferies after Carl Icahn reported a 9.4% stake in the company. Dollar General (DG), which is being seen as potentially urged as a merger target for Family Dollar based on Icahn's stake, is up 8.6% after the news... Hillshire Brands (HSH), up 4.7% after Tyson Foods (TSN) submits unilaterally binding offer to acquire the company for $8.55B... Office Depot (ODP), up 4.6% after Barron's says shares could jump over 50%... Cancer Genetics (CGIX), up 6.4% after announcing partnership with AstraZeneca (AZN). LOWER: NeuStar (NSR), down 6.3% after calling FCC posting of confidential email "troubling"... Alnylam (ALNY), down 5.8% after presenting ALN-CC5 new pre-clinical data.
News For IDIX;ACHN;MRK;FDO;DG;HITT;ADI;HSH;TSN;NSR;ALNY;CGIX;AZN;ODP From The Last 14 Days
Check below for free stories on IDIX;ACHN;MRK;FDO;DG;HITT;ADI;HSH;TSN;NSR;ALNY;CGIX;AZN;ODP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
July 22, 2014
07:08 EDTADI, HITTAnalog Devices completes tender offer for Hittite Microwave shares
Analog Devices (ADI) announced it has completed its tender offer to purchase all outstanding shares of common stock of Hittite Microwave Corporation (HITT) for $78.00 per share in cash, and ADI has accepted for payment and will promptly pay the depositary for all validly tendered shares. ADI expects to complete the acquisition of Hittite Microwave later today and will issue a press release to notify stakeholders. The tender offer expired at 12:00 midnight, New York City time, at the end of July 21, 2014. As of the expiration of the tender offer, 23,291,991 shares of Hittite Microwave common stock had been validly tendered and not validly withdrawn, representing approximately 74.2% of Hittite Microwave’s outstanding shares of common stock.
05:25 EDTAZNAdams Express, MedImmune announce clinical trial partnership
Advaxis (ADXS) has entered into a clinical trial collaboration with MedImmune, the global biologics research and development arm of AstraZeneca (AZN). The Phase I/II immunotherapy study will evaluate the safety and efficacy of MedImmune's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Advaxis' lead cancer immunotherapy vaccine, ADXS-HPV, as a treatment for patients with advanced, recurrent or refractory human papillomavirus, or HPV,-associated cervical cancer and HPV-associated head and neck cancer. Both MEDI4736 and ADXS-HPV are cancer immunotherapies, a new class of treatments that use the body's own immune system to help fight cancer. Under the terms of the agreement, MedImmune and Advaxis will evaluate the combination as a treatment for HPV-associated cervical cancer and squamous cell carcinoma of the head and neck. The Phase I part of the trial is expected to establish a recommended dose regimen of MEDI4736 with ADXS-HPV, and the Phase II portion will assess the safety and efficacy of the combination. The study will be funded and conducted by Advaxis. Results from the study will be used to determine whether further clinical development of this combination is warranted. Under the terms of the deal, MedImmune has a non-exclusive relationship with respect to HPV-driven tumour types. MedImmune has first right of negotiation for future development of combinations involving MEDI4736 and ADXS-HPV.
July 21, 2014
16:00 EDTDGOptions Update; July 21, 2014
iPath S&P 500 VIX Short-Term Futures up 65c to 28.53. Option volume leaders: AAPL FB NFLX DG CMCSA GILD PBR TWTR TSLA according to Track Data.
13:23 EDTDGHigh option volume stocks: RFMD LCI MR PII DG CTRL
Subscribe for More Information
07:47 EDTCGIXCancer Genetics to acquire Gentris
Subscribe for More Information
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
July 17, 2014
11:12 EDTIDIXOptions with decreasing implied volatility
Subscribe for More Information
July 16, 2014
18:02 EDTHITT, ADIEducation Realty to replace Hittite Microwave in S&P 600 as of 7/21 close
Subscribe for More Information
17:23 EDTTSN, HSHTyson Foods commences tender offer for Hillshire Brands for $63 per share cash
Tyson Foods (TSN) announced that it has commenced a cash tender offer for all outstanding shares of common stock of Hillshire Brands (HSH) at a price of $63.00 per share. The tender offer is being made pursuant to the previously announced merger agreement dated July 1, among the two companies and HMB Holdings, a wholly owned subsidiary of Tyson Foods. The tender offer period will expire at 12:00 midnight at the end of the day on August 12, unless the offer is extended. Tyson Foods has filed a tender offer statement on Schedule TO with the United States SEC. HMB Holdings is the acquirer in the tender offer. The Offer to Purchase contained within the Schedule TO sets out the terms and conditions of the tender offer. Hillshire Brands has also filed a Solicitation/Recommendation Statement with the SEC, which includes the recommendation of the Hillshire board of directors that Hillshire Brands stockholders tender their shares in the tender offer. Following successful completion of the tender offer, any shares not acquired in the tender offer will be acquired in a second-step merger at the same $63 per share cash price.
17:15 EDTFDOIcahn not happy with Family Dollar management
17:14 EDTFDO, DGIcahn: Dollar General CEO leaving may impact possible deal with Family Dollar
Subscribe for More Information
17:08 EDTDG, FDOIcahn disappointed Dollar General CEO leaving
Subscribe for More Information
15:54 EDTFDO, DGPeltz says 'not satisfied' with performance at Family Dollar
Subscribe for More Information
10:36 EDTAZNTreasury calls on Congress to halt inversion deals
Subscribe for More Information
10:35 EDTFDOOptions with decreasing implied volatility
Subscribe for More Information
08:01 EDTAZNAlexion names former AstraZeneca CEO David Brennan to board
Subscribe for More Information
07:59 EDTAZNTreasury Secretary urges Congress to take action on tax inversions
Subscribe for More Information
07:23 EDTCGIXRedChip Companies to hold a virtual conference
Subscribe for More Information
06:26 EDTMRKBristol-Myers lung cancer trials being underestimated, says Citigroup
After building a statistical model of Bristol-Myers' two critical registration trials for Opdivo in lung cancer, Citigroup believes the market is "materially" underestimating both Phase III trials. Citi says potential Opdivo FDA approval in 2015 in lung cancer would give Bristol-Myers an up to two year lead time versus Merck (MRK) and Roche (RHHBY). The firm estimates 2023 Opdivo revenue at $7B and reiterates a Buy rating on Bristol with a $60 price target.
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use